Q-omics provides the consensus-scored TRIM51DP profile across patient tissues and cancer cell-line models. TRIM51DP expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRIM51DP is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, TRIM51DP RNA expression shows 6,556 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, BRCA, and STAD as cancer lineages where TRIM51DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM51DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM51DP survival associations across molecular data types. TRIM51DP RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM51DP RNA expression–survival associations across cancer types. High TRIM51DP expression shows unfavorable associations in SKCM, KIRP, STAD, BLCA, DLBC and LUSC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRIM51DP RNA expression.
This table summarizes TRIM51DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM51DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM51DP shows higher tumor expression in BRCA. The BRCA box plot shows higher TRIM51DP RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .045).
This table shows molecular features associated with TRIM51DP in patient tissues and cancer cell lines. In patient samples, TRIM51DP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
